Prediabetes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Biguanide, Thiazolidinediones, Glucagon-like peptide-1 agonists (GLP-1), SGLT2 inhibitors, DPP-4 inhibitors, Others), By Age Group (Children (12-18 years), Adults (18-49), Elderly (50+)), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 351.71 Million
CAGR (2026-2031)	11.19%
Fastest Growing Segment	Biguanide
Largest Market	North America
Market Size (2031)	USD 664.63 Million

Market Overview

The Global Prediabetes Market will grow from USD 351.71 Million in 2025 to USD 664.63 Million by 2031 at a 11.19% CAGR. The Global Prediabetes Market comprises diagnostic technologies, pharmacotherapy, and digital health interventions designed to identify and treat intermediate hyperglycemia before it progresses to type 2 diabetes. The fundamental drivers supporting this market include the escalating prevalence of obesity and sedentary lifestyles which necessitate early preventive healthcare strategies to alleviate the long-term economic burden of chronic disease. Furthermore, the expansion of government-led screening initiatives and public health campaigns emphasizing preventive care significantly enhances the demand for early detection and management solutions.

However, a major challenge impeding broader market expansion is the low rate of diagnosis and limited public awareness regarding the severity of the condition. Many individuals remain undiagnosed due to the asymptomatic nature of prediabetes which restricts the addressable patient pool for pharmaceutical and monitoring products. According to the International Diabetes Federation, in 2024, an estimated 635 million adults worldwide were living with impaired glucose tolerance. This statistic underscores the substantial gap between the high prevalence of the condition and the limited number of patients actively seeking or receiving clinical intervention.

Key Market Drivers

Escalating global prevalence of obesity and sedentary lifestyles acts as the primary catalyst for the Global Prediabetes Market. As excess body weight impairs insulin sensitivity, the expanding population with high body mass index broadens the customer base for preventive interventions. This demographic shift compels healthcare systems to prioritize weight management to mitigate metabolic complications. According to the World Obesity Federation, March 2024, in the 'World Obesity Atlas 2024', the number of adults living with obesity is projected to rise to 1.53 billion by 2035. This escalating burden drives the development of lifestyle modification programs and diagnostics aimed at reversing metabolic risk factors before they progress.

The emergence of novel pharmacological interventions for weight management is also revolutionizing the therapeutic landscape. New glucagon-like peptide-1 receptor agonists provide effective options to delay disease progression. These advancements clinically demonstrate the ability to halt the transition to type 2 diabetes. According to Eli Lilly and Company, August 2024, in the 'SURMOUNT-1 study results', weekly tirzepatide injections reduced the risk of progression to type 2 diabetes by 94% among adults with prediabetes and obesity. Such efficacy validates pharmacotherapy in preventive settings. Furthermore, the market scale is evident regionally; according to the Centers for Disease Control and Prevention, in 2024, approximately 97.6 million adults in the United States had prediabetes, representing a massive addressable pool for these therapies.

Download Free Sample Report

Key Market Challenges

The primary challenge hampering the growth of the Global Prediabetes Market is the widespread lack of diagnosis resulting from the condition's largely asymptomatic nature. Unlike other chronic diseases that present with immediate or debilitating symptoms, prediabetes often develops silently, leaving millions of individuals unaware of their status. This invisibility creates a fundamental disconnect between the high prevalence of the disease and the actual demand for clinical solutions. Because patients do not feel ill, they are less likely to proactively seek screening or adopt the pharmaceutical and digital health interventions that form the core revenue streams of this market. Consequently, the "addressable" patient pool is significantly smaller than the "total" affected population, directly limiting the commercial scalability of preventive therapies and monitoring devices.

This gap in identification is starkly illustrated by recent industry data. According to the Centers for Disease Control and Prevention in 2024, more than 80 percent of the approximately 98 million adults with prediabetes in the United States were unaware they had the condition. This statistic highlights a critical barrier: without a formal diagnosis, these individuals cannot be funneled into disease management programs or prescribed preventive treatments. Manufacturers of diagnostic tests and therapeutic agents therefore face a bottleneck where the market potential is vast in theory but severely restricted in practice, as the majority of potential end-users remain outside the clinical system.

Key Market Trends

The integration of Continuous Glucose Monitoring (CGM) for non-diabetics is shifting the Global Prediabetes Market toward proactive metabolic optimization. Manufacturers are launching over-the-counter biosensors that allow individuals to visualize glycemic variability and modify behavior without prescriptions. This approach effectively engages the prediabetes demographic by providing real-time feedback on how diet and exercise impact blood sugar levels, bypassing traditional clinical barriers. The trend's commercial traction is evident; according to Fierce Biotech, January 2025, in the 'JPM25: Dexcom predicts 2025 growth' article, the Stelo over-the-counter wearable accumulated more than 140,000 users and generated $22 million in revenue shortly after launch, validating the demand for preventive monitoring.

Simultaneously, the application of artificial intelligence for early risk stratification is solving the scalability issues of human-centric prevention. AI-driven platforms now analyze user data to deliver personalized coaching, enabling cost-effective management of the vast undiagnosed prediabetic population. These tools offer continuous behavioral support that rivals traditional face-to-face methods in effectiveness. This efficacy was confirmed when, according to Johns Hopkins Medicine, October 2025, in the 'AI-Powered Diabetes Prevention Program Shows Similar Benefits to Those Led by People' report, 31.7% of participants using an AI-driven app met official diabetes risk reduction benchmarks, achieving results comparable to human-led interventions.

Segmental Insights

The Biguanide segment is emerging as the fastest-growing category within the Global Prediabetes Market, primarily driven by the extensive utilization of Metformin as a preventative pharmacotherapy. This expansion is supported by clinical guidelines from the American Diabetes Association, which recommend Metformin for high-risk individuals to delay the progression to Type 2 diabetes. Furthermore, the segment benefits from the medication's established cost-efficiency and safety profile, promoting widespread adoption among healthcare providers for patients who require medical intervention alongside lifestyle modifications.

Regional Insights

North America holds the leading position in the global prediabetes market due to the rising prevalence of lifestyle-associated risk factors such as obesity. This dominance is supported by well-established healthcare infrastructure and proactive government initiatives that emphasize early disease detection. For instance, the Centers for Disease Control and Prevention facilitates the National Diabetes Prevention Program, which significantly raises public awareness and encourages screening. Furthermore, the presence of major industry players and favorable reimbursement policies for preventive care fosters a conducive environment for market expansion across the region.

Recent Developments

• In September 2024, Abbott announced the U.S. commercial availability of Lingo, its first over-the-counter continuous glucose monitoring system tailored for consumers seeking to improve their metabolic wellness. The biowearable device is designed for adults who are not on insulin, specifically targeting the general population and those with prediabetes who wish to understand their body's reaction to food and exercise. By tracking glucose spikes and providing personalized coaching through a mobile application, the system empowers users to adopt healthier habits and prevent the progression of metabolic issues. This launch signifies a major expansion of glucose monitoring technology into the preventive health market.
• In August 2024, Omada Health entered into a strategic partnership with the State of Alaska to expand access to its virtual chronic care programs for state employees and their families. This collaboration aims to deliver the company's evidence-based Diabetes Prevention Program to individuals living in remote and rural areas where access to in-person healthcare is often limited. By leveraging a digital platform that combines data science with human coaching, the initiative seeks to reduce the prevalence of type 2 diabetes among at-risk populations. The partnership focuses on improving health equity by ensuring that specialized prediabetes care is available to residents across the state's vast geography.
• In June 2024, Virta Health presented new research findings at the American Diabetes Association’s 84th Scientific Sessions regarding the efficacy of its remote care model for diverse populations. The company highlighted outcomes from a study comparing rural and urban members with prediabetes, demonstrating that its personalized, nutrition-first approach delivered significant health improvements regardless of the patient's location. The data revealed that members in both groups achieved similar positive results in weight loss and blood sugar control over one year. This research underscores the potential of virtual health interventions to bridge care gaps and effectively manage prediabetes in underserved communities.
• In March 2024, Labcorp launched a comprehensive Weight Loss Management portfolio designed to support individuals and physicians in guiding weight management and diabetes prevention decisions. This new offering includes specific baseline tests to measure essential markers such as hemoglobin A1c, cholesterol, and thyroid function, which are critical for evaluating metabolic health and prediabetes risk. The launch addresses the growing demand for personalized health insights, particularly for patients considering lifestyle modifications or glucagon-like peptide-1 (GLP-1) medications. By providing accessible testing solutions, the company aims to facilitate early intervention and effective management of conditions like prediabetes and obesity.

Key Market Players

• Novo Nordisk A/S
• Valbiotis
• RESVERLOGIX
• Caelus Health
• Scimar
• Boston Pharmaceuticals
• APHAIA PHARMA AG
• AstraZeneca Plc
• Bristol-Myers Squibb Company
• Pfizer Inc

By Drug Class	By Age Group	By Region
Biguanide Thiazolidinediones Glucagon-like peptide-1 agonists (GLP-1) SGLT2 inhibitors DPP-4 inhibitors Others	Children (12-18 years) Adults (18-49) Elderly (50+)	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Prediabetes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Prediabetes Market, By Drug Class:

• Biguanide
• Thiazolidinediones
• Glucagon-like peptide-1 agonists (GLP-1)
• SGLT2 inhibitors
• DPP-4 inhibitors
• Others

• Prediabetes Market, By Age Group:

• Children (12-18 years)
• Adults (18-49)
• Elderly (50+)

• Prediabetes Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE